Breaking News: Lanier Biotherapeutics Receives U.S. Patent for IL-25 Binding Molecules – A Major Milestone in the World of Biotechnology!

Lanier Biotherapeutics Announces Issuance of U.S. Patent for IL-25 Binding Monoclonal Antibodies BOGART, Georgia, Nov. 14, 2022 (GLOBE NEWSWIRE) — Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, Type 2 inflammatory diseases, and oncology, today announced that the United States Patent and Trademark Office has issued U.S. Patent…

Read More

Longeveron Inc. Delivers Corporate Update and Reveals Third Quarter 2022 Financial Results: A Look into the Future of Biotechnology

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results Achieving Clinical and Regulatory Milestones Longeveron Inc. has achieved key clinical and regulatory milestones across its clinical pipeline. One notable accomplishment is the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease. This milestone marks a significant step forward in the…

Read More

Palisade Bio Crushes Q3 Earnings and Spills the Tea on Business Growth: A Must-Read Recap!

Welcome to the World of Palisade Bio! Financial Results and Business Update Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) Hey there, fellow health enthusiasts! Have you heard the latest news from Palisade Bio, Inc.? This innovative clinical stage biopharmaceutical company, traded as Nasdaq: PALI, is making waves in the world of gastrointestinal (GI) therapies. In…

Read More

Lumos Pharma Reports Positive Interim Results from Two Phase 2 Trials for Oral Lum-201 in Treating Moderate Pediatric Growth Hormone Deficiency

Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency Introduction Lumos Pharma recently reported positive interim results from two Phase 2 trials evaluating LUM-201, a potential breakthrough in the treatment of Pediatric Growth Hormone Deficiency (PGHD). The trials have shown promising growth in pediatric…

Read More